PROVIDER***ALERT***

AmeriHealth Caritas Louisiana

To: **AmeriHealth Caritas Louisiana Providers**

Date: **September 26, 2025**

Subject: **Cervical Cancer Screening (CCS-E)- HPV Self Collection**

Summary: The FDA approved HPV self-collection in clinics, expanding access to cervical cancer screening for those who may face barriers to traditional screening modalities.[1]

The FDA recently cleared use of human papillomavirus (HPV) patient self-collection modalities in the clinical setting. In addition to established methods like Pap testing, co-testing, and primary HPV testing, HPV self-collection offers a valuable testing option to support our members. HPV self-collection testing aligns with current NCQA HEDIS CCS-E measure specifications. By incorporating self-collection into your practice, you can help lower care barriers and offer more personalized screening options.

HPV self-collection allows patients to collect their own vaginal sample in a clinical environment using a simple swab. This approach can be effective for reaching individuals who are under screened due to factors such as discomfort with pelvic exams, cultural or language barriers, lack of access to care, or past trauma. By offering self-collection, providers can expand screening access, promote early detection of cervical cancer, and support equitable care delivery across diverse populations.

How do I Order HPV Self-Collection Swabs and Obtain Additional Information?

Educational resources are available for both providers and members in multiple languages, written, and video format. Contact your LabCorp or Quest account executive to order HPV self-collection kits and obtain educational materials. Visit LabCorp or Quest's website to learn more: ***https://www.labcorp.com/tests/507401/self-collection-in-office-or-patient-service-center-high-risk-human-papillomavirus-hpv-with-genotyping-vaginal-swab***

https://newsroom.questdiagnostics.com/2025-04-02-Quest-Diagnostics-Introduces-HPV-Specimen-Self-Collection-for-Cervical-Cancer-Screening

[1] Daponte N, Valasoulis G, Michail G, Magaliou I, Daponte AI, Garas A, Grivea I, Bogdanos DP, Daponte A. HPV-Based Self-Sampling in Cervical Cancer Screening: An Updated Review of the Current Evidence in the Literature. Cancers (Basel). 2023 Mar 8;15(6):1669. doi: 10.3390/cancers15061669. PMID: 36980555; PMCID: PMC10046242.

Cervical Cancer Screening HEDIS® Measure Guidelines:

The percentage of women 21-64 years of age who were screened for cervical cancer using any of the following criteria:

- Women ages 21-64 who had cervical cytology performed within the last 3 years.
- Women ages 30-64 who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women ages 30-64 who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

Questions: Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please get in touch with AmeriHealth Caritas Louisiana Provider Services at 1-888-922-0007 or your Provider Network Management Account Executive.

Missed an alert? You can find a complete list of provider alerts on our website's Provider Newsletters and Updates page.

Need to update your provider information? Send full details to network@amerihealthcaritasla.com.